Xiao Meng, Wang Xu, Chen Wantao
Department of Oral and Maxillofacial-Head and Neck Oncology and Faculty of Oral and Maxillofacial Surgery, Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, and Shanghai Research Institute of Stomatology and Shanghai Key Laboratory of Stomatology, Shanghai, China.
Histol Histopathol. 2015 Oct;30(10):1171-83. Epub 2015 Jun 12.
We aimed to analyse and summarise the potential value of the clinical use of p53-related alterations as cancer biomarkers. A systematic search and collection of the published meta-analyses on p53-related alterations and cancers in the past 5 years was conducted through appropriate queries in the PubMed database. We then composed "grey-scale" tables to show the significant levels for each variant, and the potential heterogeneity was subsequently discussed. The data show that p53-related alterations are extremely complex biomarkers in terms of their clinical translation. Together with the experimental studies on p53-related alterations, a gold-standard approach is still in need of development, with more evidence from clinical studies with large, prospectively planned cohorts, to fully understand its potential as a cancer biomarker.
我们旨在分析和总结p53相关改变作为癌症生物标志物临床应用的潜在价值。通过在PubMed数据库中进行适当查询，对过去5年发表的关于p53相关改变与癌症的荟萃分析进行了系统检索和收集。然后我们编制了“灰度”表以显示每个变体的显著水平，并随后讨论了潜在的异质性。数据表明，就临床转化而言，p53相关改变是极其复杂的生物标志物。连同对p53相关改变的实验研究一起，仍需要开发一种金标准方法，需要有来自大型前瞻性队列临床研究的更多证据，以充分了解其作为癌症生物标志物的潜力。
